A

Amylyx Pharmaceuticals

Biopharmaceutical company developing neurodegenerative therapies

Senior Director, Pharmacometrics

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • A PhD, PharmD, MD, or equivalent advanced degree in Pharmacometrics, Clinical Pharmacology, Pharmacokinetics, Pharmaceutical Sciences, Biomedical Engineering, Statistics, or a related quantitative discipline is required.
  • Typically 12–15+ years of relevant biotechnology or pharmaceutical industry experience, including substantial pharmacometrics and model-informed drug development experience.
  • Demonstrated expertise in population pharmacokinetics (PopPK), pharmacokinetic/pharmacodynamic (PK/PD) analysis, exposure-response analysis, modeling and simulation, and quantitative clinical pharmacology across multiple phases of clinical development.
  • Experience developing quantitative strategies, independently executing or overseeing complex analyses, critically evaluating results, and translating findings into clear development recommendations.
  • Demonstrated experience supporting regulatory submissions and preparing materials for, or interacting with, the FDA or other health authorities.
  • Proficiency with commonly used pharmacometric modeling and simulation tools such as NONMEM, Monolix, R, Phoenix NLME, or comparable platforms.
  • Demonstrated ability to manage external consultants, contract research organizations (CROs), and technical vendors while operating effectively in a dynamic, growing biotechnology organization.

Responsibilities

  • Develop and lead pharmacometrics strategies across assigned clinical development programs, aligning model-informed drug development plans with clinical and regulatory objectives.
  • Lead population pharmacokinetic (PopPK), PK/PD, exposure-response, disease progression, and other quantitative modeling and simulation activities to inform dose and regimen selection, trial design, patient population selection, and interpretation of clinical data.
  • Provide quantitative input into clinical development plans, protocols, statistical analysis plans, integrated development plans, regulatory strategies, and key program decisions throughout the development lifecycle.
  • Support regulatory submissions and interactions, including INDs, NDAs/BLAs, briefing documents, health authority responses, and pharmacometrics or clinical pharmacology components of submission documents.
  • Integrate clinical pharmacology, biomarker, efficacy, safety, and other relevant data into modeling strategies that support development recommendations and benefit-risk assessment.
  • Partner cross-functionally with Clinical Pharmacology, Clinical Development, Biostatistics, Data Science, Clinical Operations, Regulatory Affairs, Medical Affairs, CMC, and other functions, communicating complex results clearly to multidisciplinary teams and senior leadership.
  • Provide scientific oversight of external pharmacometrics consultants, CROs, and vendors, including scopes of work, analysis review, deliverable assessment, and adherence to scientific, regulatory, and quality standards.
  • Advance functional capabilities, processes, standards, and best practices; mentor colleagues, identify emerging quantitative methodologies, and potentially build and lead internal pharmacometrics capabilities as the organization grows.

Desired Qualifications

  • Experience supporting late-stage clinical development and regulatory submissions.
  • Knowledge of evolving regulatory expectations and guidance related to population pharmacokinetics, exposure-response analyses, and model-informed drug development.
  • Experience building pharmacometrics capabilities, mentoring technical colleagues, or leading a pharmacometrics function.

About the Company

Amylyx Pharmaceuticals

Biopharmaceutical company developing neurodegenerative therapies

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, with a focus on ALS and Alzheimer's disease. Its main asset is AMX0035, currently in clinical trials, including the CENTAUR study for ALS and the PEGASUS study for late mild cognitive impairment or early dementia due to Alzheimer’s disease. The company advances products through rigorous, randomized, double-blind, placebo-controlled trials to demonstrate safety and efficacy before pursuing commercialization. In addition to research, Amylyx engages in awareness and community campaigns to support patients, caregivers, and researchers. The company aims to bring validated therapies to market to improve patient outcomes and generate revenue by selling treatments to healthcare providers and patients.

Company size
51-200
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2013

Recently Posted Jobs

Explore more opportunities at Amylyx Pharmaceuticals

See more jobs